September 2024
The global oligonucleotide synthesis market size is estimated at US$ 5.59 billion in 2024 and is projected to grow to US$ 20.31 billion by 2034, rising at a compound annual growth rate (CAGR) of 13.78% from 2024 to 2034. The growing demand for the biotechnology industry drives the market’s growth.
Unlock Infinite Advantages: Subscribe to Annual Membership
The chemical process via which nucleotides are precisely joined to create the required sequencing result is known as oligonucleotide synthesis. Packed-bed columns are frequently employed in continuous solid-phase synthesis for the production of oligonucleotides. A batch slurry reaction is used in certain situations. As sequence-specific binding agents, oligonucleotides are employed in a wide range of biological and forensic applications to identify the presence of a particular target DNA sequence. Throughout history, modified oligos have played a significant role in a wide range of life science applications, particularly in clinically-based settings such as molecular diagnostics and therapies.
After targets are found, the creation and alteration of therapeutic oligonucleotides take center stage. An important element played by artificial intelligence is that which our partner Sylentis uses in their exclusive sirFinder program. Sophisticated algorithms examine extensive datasets to forecast the effectiveness of the oligonucleotides that are developed. With the help of tools like these, gene therapy may now be carried out more accurately and quickly, reaching new heights in the process.
For instance,
| Company Name | Asahi Kasei Bio Process |
| Headquarters | Tokyo, Japan, Asia Pacific |
| Recent Development | In April 2024, in the rapidly developing field of oligonucleotide therapies, Asahi Kasei Bioprocess (AKB), a division of the Asahi Kasei Group, and Axolabs established a strategic collaboration. The partners will work together to construct a state-of-the-art cGMP oligonucleotide production facility in Berlin that will occupy 59,000 square feet or around 5,481 square meters. Through this collaboration, patient quality of life will be enhanced globally by developing and commercializing oligonucleotide-based medicines more quickly. |
| Company Name | Codexis Inc. |
| Headquarters | California, U.S., North America |
| Recent Development | In May 2024, the production of RNA-based medicines will be aided by the announcement made by top enzyme engineering business Codexis, Inc. that it has effectively produced an oligonucleotide using an enzymatic process. |
The market for oligonucleotide synthesis is significantly driven by the rising incidence of genetic illnesses, which include ailments like cancer, uncommon diseases, and genetic abnormalities. According to World Health Organization (WHO) research, millions of individuals worldwide are significantly impacted by genetic illnesses. To produce targeted medicines and molecular diagnostics specific to particular genetic variants, oligonucleotides are essential. The need for oligonucleotide-based therapies is growing as our understanding of the genetic underpinnings underlying disease processes becomes more profound.
For instance,
Because the number of mistakes increases with the length of the oligonucleotide being synthesized, side reactions provide practical limits on the length of synthetic oligonucleotides, up to around 200 nucleotide residues.
Up until recently, traditional solid-phase synthesis has successfully met the need for oligonucleotide-based medications. Nonetheless, several items that are now undergoing advanced phases of clinical studies are anticipated to have a collective demand in metric tons in the near future. Process chemists now consider it of utmost importance to manufacture these goods on a massive scale. Clearly, significant efforts are being made to create a scalable, cost-effective, green chemical process that is environmentally safe and effective for oligonucleotide production.
By product & service, the services segment held the largest share of the oligonucleotide synthesis market in 2023. Numerous businesses provide custom oligo synthesis services for a range of molecular biology applications. The remarkable rate of advancement in genomic research methodologies highlights the demand for quick, affordable, and high-quality oligonucleotides. Chromatography is a method that uses differential adsorption on an adsorbent surface to separate the constituents of a mixture. Furthermore, it could be advantageous to characterize the finished product before using it. Mass spectrometry, frequently in conjunction with chromatography, is an effective technique for this.
For instance,
By application, the PCR primers segment dominated the oligonucleotide synthesis market in 2023. The oligonucleotide synthesis process, which uses PCR-based amplification, is a crucial technique in molecular biology because it offers a flexible way to amplify DNA and modify it to create distinct molecules. Research on gene expression, genetic testing, and cloning all depend on this methodology.
By region, North America dominated the oligonucleotide synthesis market share by 41.02% in 2023. Influential research and development expenditures, in conjunction with the region's thriving biotechnology and pharmaceutical industries, have driven market developments. Further driving the rising need for oligonucleotides is the boom in genomic research and gene therapy projects, including those started by top universities. North America has played a major role in propelling the oligonucleotide synthesis market's notable expansion, as evidenced by its well-established infrastructure, positive regulatory environment, and increased awareness of genetic abnormalities. Strong medical facilities, a large number of major business leaders, an increase in cases of viral diseases, and a rise in research projects. These elements strengthen the area's position as a pioneer in the development and use of oligonucleotide synthesis methods.
| June 2024 | ||
| Exports | Imports | |
| Total | 5648 | 8791 |
| May 2024 | ||
| Exports | Imports | |
| Total | 5257 | 9416 |
| June 2024 | ||
| Exports YTD | Imports YTD | |
| Total | 28888 | 56927 |
| June 2023 | ||
| Exports YTD | Imports YTD | |
| Total | 24404 | 41653 |
By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. Advances in genomic research and the broad use of PCR and sequencing technology are the main drivers of this explosive expansion. As they grow their business potential, genomics is becoming increasingly important to China, India, and Japan. A growing number of product approvals and launches are also taking place in the area, which is helping the oligonucleotide synthesis market grow.
The Genomics India Conference is returning! This conference, the fourth in the Genomics India series, will showcase cutting-edge research into the most recent developments in genetic technology, with an emphasis on disseminating ground-breaking discoveries. For academics, physicians, and other professionals who want to keep current on the most recent findings and advancements in the field of genetics, GIC2024 is an excellent platform. There will be a ton of subjects discussed, such as the use of genomics in the fields of infectious diseases, cancer genomics, inherited diseases, diagnostics, biopharma, vaccine development, and agriculture. A stellar lineup of speakers and panelists, including well-known figures from the Indian and global diaspora, will be featured at the conference. Their talks will be distributed across three days and several sessions.
India is also focusing on sequencing human genomes, which will continuously require the synthesis of oligonucleotides. Till today, a lot of samples have been collected and used for genome sequencing. There are biobanks across India that save and reserve samples from different ethnicities.
| SI No | Institute Name | No. of Samples Received for Biobanking |
| 1. | CBR | 3003 |
| 2. | CCMB | 1506 |
| 3. | IGIB | 3131 |
| 4. | NIBMG | 1260 |
| 5. | AIIMS-J | 1505 |
| 6. | IISER-P | 1153 |
| 7. | RGCB | 1851 |
| 8. | NIMHANS | 519 |
| 9. | ILS-B | 940 |
| 10. | GBRC | 1720 |
| 11. | MZU | 592 |
| 12. | SKIMS | 1274 |
| 13. | IBSD | 777 |
| Total | 19231 | |
By Product & Service
By Application
By Region
September 2024
September 2024
September 2024
September 2024
Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.